29 July 2026
: Case report 
Catheter-Directed Thrombolysis and Direct Oral Anticoagulant Class Switch to Prevent Pulmonary Embolism From Large Inferior Vena Cava Thrombus
Management of emergency care, Rare coexistence of disease or pathology
Takashi Araki ABCDEF 1*, Kazuyuki Nishimura DEF 1, Yusuke Hitora DEF 1, Kenichiro Yokoi DEF 1, Takashi Yamada DEF 1, Manabu Miura DEF 1DOI: 10.12659/AJCR.953199
Am J Case Rep 2026; 27:e953199
Table 1 Laboratory data measured on admission.
| WBC, ×10/μL | 67 |
| Hemoglobin, g/dL | 14.4 |
| Platelets, ×10/μL | 14.7 |
| AST, IU/L | 35 |
| ALT, IU/L | 20 |
| LDH, IU/L | 252 |
| T.Bil, mg/dL | 0.6 |
| CK, IU/L | 35 |
| BUN, mg/dL | 12.7 |
| Creatinine, mg/dL | 0.83 |
| eGFR, mL/min/1.73 m | 58.6 |
| hsCRP, mg/dL | 4.9 |
| hsTnI, pg/mL | 89.3 |
| BNP, pg/mL | 60.4 |
| APTT, s | 26.8 |
| PT-INR | 0.96 |
| Fibrinogen, mg/dL | 320 |
| Antithrombin-III,% | 76 |
| PC activity,% | 101 |
| PS activity,% | 72 |
| LA (Russell’s viper venom time) | 1.1 (negative) |
| Anti-CL2GPI antibody, U/mLβ | 1.2 (negative) |
| Anti-2 GPI IgG antibody, U/mLβ | 0.7 (negative) |
| Anticardiolipin IgG antibody, U/m | 4.0 (negative) |
| Antinuclear antibody | <1: 40 (negative) |
| β2 GPI, beta-2 glycoprotein 1; ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; CK, creatine kinase; CLβ2GPI, cardiolipin-beta2 glycoprotein 1 complex; eGFR, estimated glomerular filtration rate; hsCRP, high sensitivity c-reactive protein; IgG, immunoglobulin G; hsTnI, high-sensitivity troponin I; LA, lupus anticoagulant; LDH, lactate dehydrogenase; PC, protein c; PS, protein s; PT-INR, prothrombin time-international normalized ratio; T.Bil, total bilirubin; WBC, white blood cells. | |